Analyst Reco. Demant A/S Berne S.E.

Equities

Delayed Berne S.E. Other stock markets 17:00:03 15/11/2023 GMT			5-day change	1st Jan Change
34.92 ^CHF	-.--%		-19.92%	-6.81%

06-26	Demant Flags Delay in Completion of Communications Business' Strategic Review	MT
05-29	UK’s Competition Regulator Closes Cochlear-Demant Deal	MT

DEMANT : Q1 sales miss; organic growth guidance unchanged	05-06
DEMANT : In-line Q4; markets cheer the promising takeaways for 2024	02-06
DEMANT : Sales broadly in-line; guidance narrowed	11-07
Chinese headwinds could be more severe than expected	22/09/23
DEMANT : Better-than-expected Q2 + a guidance upgrade	22/08/23
DEMANT : Better-than-expected Q2 + a guidance upgrade	16/08/23
DEMANT : New product launches + a rebound in hearing aids are encouraging	03/05/23
DEMANT : Strong Q1 + guidance upgrade	25/04/23
DEMANT : Strong Q1 + guidance upgrade	18/04/23
DEMANT : Strong Q4 + promising takeaways	05/04/23
DEMANT : Strong Q4 + promising takeaways	07/02/23
DEMANT : Soft Q3 + consecutive guidance downgrade	02/11/22
DEMANT : Soft Q2 + guidance downgrade	17/08/22
DEMANT : In line Q1, full year guidance reiterated	05/05/22
DEMANT : Hearing Healthcare recovery continues; capitalise the entry opportunity	09/02/22
DEMANT : Marginal guidance upgrade won’t trigger a change in stance	02/11/21
DEMANT : 2021 CMD: ambitious targets unveiled	29/09/21
DEMANT : As communications slows, hearing healthcare takes the lead; FY21 outlook upgraded	13/08/21
ANALYST RECOMMENDATIONS : American Express, HSBC, CyrusOne, Microsoft, Vodafone...	18/06/21
DEMANT : Better-than-expected operational performance ytd; FY21 targets raised	04/05/21

No results for this search

DEMANT : Q1 sales miss; organic growth guidance unchanged

May 06, 2024 at 04:18 pm